Triletide
Source Triletide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Triletide is a synthetic tripeptide investigated in the mid‑1980s as a cytoprotective agent for peptic ulcer disease. Small randomised trials evaluated oral doses of 1–2 g per day in patients with gastric or duodenal ulcers, reporting accelerated ulcer healing and relief of heartburn, epigastric pain and antacid use. The compound was compared with antacids, ranitidine, cimetidine and carbenoxolone, and was generally well tolerated.
Mechanism of Action
Triletide is described as enhancing the mucosal defence capacity of the gastroduodenal lining. Experimental reports indicate it stimulates synthesis of protective mucus and antagonises thromboxane A2, a mediator that can impair mucosal blood flow and increase injury. By bolstering mucus production and modulating inflammatory pathways, the peptide is thought to create a more resistant gastric and duodenal surface, allowing ulcers to heal more rapidly.
What the Research Shows
Between 1985 and 1986, nine clinical investigations involving 10–30 out‑patients each examined triletide for active gastric or duodenal ulcers. Dose‑finding studies showed a log‑linear relationship between dose (1–2 g/day) and healing, with an estimated ED50 of 1.2 g/day and faster symptom regression at higher doses. Compared with antacids, triletide produced significantly greater symptom improvement and higher endoscopic healing rates. In head‑to‑head trials with ranitidine, cimetidine or carbenoxolone, triletide achieved comparable pain relief and healing, sometimes with a faster onset, and was similarly well tolerated. Adverse events were mild and infrequent, and routine laboratory parameters remained unchanged.
Reported Benefits
The available trials suggest that triletide can accelerate ulcer healing, reduce heartburn and epigastric pain, and lower the need for concomitant antacids. Healing rates appeared dose‑dependent, with doses of 1.5–2 g/day achieving the greatest effect. Symptom relief was observed within two weeks in several studies, and overall tolerance was comparable to standard therapies such as antacids or H2‑blockers.
Limitations of the Evidence
Evidence is limited to small, short‑term studies conducted in the mid‑1980s, with sample sizes rarely exceeding 30 participants. No long‑term follow‑up, larger multicentre trials, or modern comparative data are available. The studies did not assess recurrence rates, quality‑of‑life outcomes, or interactions with other ulcer medications. Regulatory status and contemporary safety profiling remain undocumented.
Safety Considerations
Across the trials, triletide was generally well tolerated. Reported adverse effects were minimal, including one case of increased constipation and another of mild headache and dizziness, neither of which could be definitively linked to the drug. Routine haematology, biochemistry and renal function tests showed no significant changes. Unlike carbenoxolone, triletide did not affect blood pressure or serum potassium in the reported studies.
How It Is Administered
Triletide was administered orally, typically divided into three daily doses. Investigated daily regimens ranged from 1 g to 2 g, most commonly 1.5 g per day, given over 6–8 weeks in ulcer patients. Formulations were described as tablets or powders taken with water, but specific product details were not provided.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleModerateMaggi CA, Ferrari D1985-01-01T00:00:00.000000Z
- Journal ArticleModerateGandolfi L, Solmi L1985-01-01T00:00:00.000000Z
- Journal ArticleModerateTrabucchi E, et al.1985-01-01T00:00:00.000000Z
- Journal ArticleModerateWaucquez JL1985-01-01T00:00:00.000000Z
- Journal ArticleModerateCampisi D, et al.1985-01-01T00:00:00.000000Z
- Journal ArticleModeratePrimbs P1985-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of ulcer condition has triletide been studied for?
All published trials evaluated triletide in patients with active gastric or duodenal ulcers, confirming endoscopic diagnosis before treatment.
How does triletide compare to standard ulcer medicines like ranitidine or cimetidine?
In head‑to‑head studies, triletide achieved pain relief and ulcer healing comparable to ranitidine and cimetidine, with some reports of a faster onset of symptom improvement.
Is triletide approved for clinical use?
The abstracts do not mention any regulatory approval; triletide remains an investigational compound with no documented marketing status.
What side effects might a patient experience?
Mild adverse events such as increased constipation, headache or dizziness were reported in isolated cases; no serious laboratory abnormalities or cardiovascular effects were observed.
What is Triletide?
Triletide is a synthetic tripeptide investigated in the mid‑1980s as a cytoprotective agent for peptic ulcer disease. Small randomised trials evaluated oral doses of 1–2 g per day in patients with gastric or duodenal ulcers, reporting accelerated ulcer healing and relief of heartburn, epigastric pain and antacid use. The compound was compared with antacids, ranitidine, cimetidine and carbenoxolone, and was generally well tolerated.